Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles Eigenbrot

Showing results (61-70 of 102) with videos related to

Pageof 11
Sort By:
Bioorganic & Medicinal Chemistry Letters|September 10, 2013
Identification of 2-amino-5-aryl-pyrazines as inhibitors of human lactate dehydrogenaseBenjamin P Fauber, Peter S Dragovich, Jinhua Chen, et al.
Cancer Cell|March 22, 2016
Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2Scott A Foster, Daniel M Whalen, Ayşegül Özen, et al.
ACS Medicinal Chemistry Letters|May 31, 2021
Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a Pyridopyridazinone pan-RAF Kinase InhibitorMalcolm P Huestis, Matthew R Durk, Charles Eigenbrot, et al.
ACS Chemical Biology|August 30, 2016
Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 MutationsAdam R Johnson, Pawan Bir Kohli, Arna Katewa, et al.
Journal of Medicinal Chemistry|June 12, 2014
Property- and structure-guided discovery of a tetrahydroindazole series of interleukin-2 inducible T-cell kinase inhibitorsJason D Burch, Kevin Lau, John J Barker, et al.
Journal of Medicinal Chemistry|April 7, 2015
Tetrahydroindazoles as Interleukin-2 Inducible T-Cell Kinase Inhibitors. Part II. Second-Generation Analogues with Enhanced Potency, Selectivity, and Pharmacodynamic Modulation in VivoJason D Burch, Kathy Barrett, Yuan Chen, et al.
Journal of Medicinal Chemistry|October 16, 2012
Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitorsEmily J Hanan, Anne van Abbema, Kathy Barrett, et al.
ACS Medicinal Chemistry Letters|January 29, 2016
Pyridones as Highly Selective, Noncovalent Inhibitors of T790M Double Mutants of EGFRMarian C Bryan, Daniel J Burdick, Bryan K Chan, et al.
Cancer Cell|October 22, 2011
A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodiesGabriele Schaefer, Lauric Haber, Lisa M Crocker, et al.
Bioorganic & Medicinal Chemistry Letters|May 1, 2013
Identification of substituted 2-thio-6-oxo-1,6-dihydropyrimidines as inhibitors of human lactate dehydrogenasePeter S Dragovich, Benjamin P Fauber, Laura B Corson, et al.
Pageof 11

Showing results (61-70 of 102) with videos related to

Sort By:
Pageof 11
Bioorganic & Medicinal Chemistry Letters|September 10, 2013
Identification of 2-amino-5-aryl-pyrazines as inhibitors of human lactate dehydrogenaseBenjamin P Fauber, Peter S Dragovich, Jinhua Chen, et al.
Cancer Cell|March 22, 2016
Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2Scott A Foster, Daniel M Whalen, Ayşegül Özen, et al.
ACS Medicinal Chemistry Letters|May 31, 2021
Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a Pyridopyridazinone pan-RAF Kinase InhibitorMalcolm P Huestis, Matthew R Durk, Charles Eigenbrot, et al.
ACS Chemical Biology|August 30, 2016
Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 MutationsAdam R Johnson, Pawan Bir Kohli, Arna Katewa, et al.
Journal of Medicinal Chemistry|June 12, 2014
Property- and structure-guided discovery of a tetrahydroindazole series of interleukin-2 inducible T-cell kinase inhibitorsJason D Burch, Kevin Lau, John J Barker, et al.
Journal of Medicinal Chemistry|April 7, 2015
Tetrahydroindazoles as Interleukin-2 Inducible T-Cell Kinase Inhibitors. Part II. Second-Generation Analogues with Enhanced Potency, Selectivity, and Pharmacodynamic Modulation in VivoJason D Burch, Kathy Barrett, Yuan Chen, et al.
Journal of Medicinal Chemistry|October 16, 2012
Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitorsEmily J Hanan, Anne van Abbema, Kathy Barrett, et al.
ACS Medicinal Chemistry Letters|January 29, 2016
Pyridones as Highly Selective, Noncovalent Inhibitors of T790M Double Mutants of EGFRMarian C Bryan, Daniel J Burdick, Bryan K Chan, et al.
Cancer Cell|October 22, 2011
A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodiesGabriele Schaefer, Lauric Haber, Lisa M Crocker, et al.
Bioorganic & Medicinal Chemistry Letters|May 1, 2013
Identification of substituted 2-thio-6-oxo-1,6-dihydropyrimidines as inhibitors of human lactate dehydrogenasePeter S Dragovich, Benjamin P Fauber, Laura B Corson, et al.
Pageof 11